Column Group III Gp, LP sold $505k of TNYA
owner at Tenaya Therapeutics, Inc.. 829,734 shares at an average of $0.61, traded Feb 20, 2026, filed Feb 24, 2026.
Score components
- +12Role10% owner
- +18Trade size$505k at market
- +10Share of holdings soldSold 35% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-067007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 20, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -245,965 | $0.61 | $151k | 2,102,218 | Feb 24, 2026 |
| Feb 20, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -277,769 | $0.61 | $171k | 2,374,048 | Feb 24, 2026 |
| Feb 23, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -143,709 | $0.60 | $86k | 1,958,509 | Feb 24, 2026 |
| Feb 23, 2026 | SOpen-market sale Common Stockindirect: See Footnote | -162,291 | $0.60 | $97k | 2,211,757 | Feb 24, 2026 |
Related signals
Other insiders at Tenaya Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 65Notable | Tenaya Therapeutics, Inc. | Column Group III Gp, LP owner | $2.4M 4,170,266 shares | -213% | |
| 33Weak | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $9,557 14,862 shares | -3% | |
| 75Notable | Tenaya Therapeutics, Inc. | Column Group III Gp, LP owner | $3.0M 4,400,290 shares | -100% | |
| 40Moderate | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $4,158 3,126 shares | -1% | |
| 30Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $1,818 1,367 shares | -1% | |
| 30Weak | Tenaya Therapeutics, Inc. | Whittemore Tingley Chief Medical Officer | $3,826 2,877 shares | -2% | |
| 40Moderate | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $18k 14,533 shares | -5% | |
| 30Weak | Tenaya Therapeutics, Inc. | Tomohiro Higa SVP, Finance | $3,711 2,962 shares | -3% | |
| 30Weak | Tenaya Therapeutics, Inc. | Whittemore Tingley Chief Medical Officer | $6,331 5,053 shares | -3% | |
| 40Moderate | Tenaya Therapeutics, Inc. | Faraz Ali Chief Executive Officer | $1,412 3,189 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.